Suppr超能文献

优化丝氨酸/苏氨酸磷酸酶 PPM1D(Wip1)的环状肽抑制剂。

Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).

机构信息

Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Biochemistry. 2011 May 31;50(21):4537-49. doi: 10.1021/bi101949t. Epub 2011 May 9.

Abstract

PPM1D (PP2Cδ or Wip1) was identified as a wild-type p53-induced Ser/Thr phosphatase that accumulates after DNA damage and classified into the PP2C family. It dephosphorylates and inactivates several proteins critical for cellular stress responses, including p38 MAPK, p53, and ATM. Furthermore, PPM1D is amplified and/or overexpressed in a number of human cancers. Thus, inhibition of its activity could constitute an important new strategy for therapeutic intervention to halt the progression of several different cancers. Previously, we reported the development of a cyclic thioether peptide with low micromolar inhibitory activity toward PPM1D. Here, we describe important improvements in the inhibitory activity of this class of cyclic peptides and also present a binding model based upon the results. We found that specific interaction of an aromatic ring at the X1 position and negative charge at the X5 and X6 positions significantly increased the inhibitory activity of the cyclic peptide, with the optimized molecule having a K(i) of 110 nM. To the best of our knowledge, this represents the highest inhibitory activity reported for an inhibitor of PPM1D. We further developed an inhibitor selective for PPM1D over PPM1A with a K(i) of 2.9 μM. Optimization of the cyclic peptide and mutagenesis experiments suggest that a highly basic loop unique to PPM1D is related to substrate specificity. We propose a new model for the catalytic site of PPM1D and inhibition by the cyclic peptides that will be useful both for the subsequent design of PPM1D inhibitors and for identification of new substrates.

摘要

PPM1D(PP2Cδ 或 Wip1)被鉴定为一种野生型 p53 诱导的丝氨酸/苏氨酸磷酸酶,在 DNA 损伤后积累,并被归类为 PP2C 家族。它使包括 p38 MAPK、p53 和 ATM 在内的几种对细胞应激反应至关重要的蛋白质去磷酸化和失活。此外,PPM1D 在许多人类癌症中扩增和/或过表达。因此,抑制其活性可能构成一种重要的新策略,用于治疗干预以阻止几种不同癌症的进展。以前,我们报道了一种具有低微摩尔抑制活性的环状硫醚肽对 PPM1D 的开发。在这里,我们描述了对这类环状肽的抑制活性的重要改进,并且还基于结果提出了一个结合模型。我们发现 X1 位置的芳环和 X5 和 X6 位置的负电荷的特异性相互作用显著提高了环状肽的抑制活性,优化后的分子的 K(i)为 110 nM。据我们所知,这代表了报道的 PPM1D 抑制剂的最高抑制活性。我们进一步开发了一种对 PPM1D 具有选择性的抑制剂,其对 PPM1A 的 K(i)为 2.9 μM。对环状肽的优化和突变体实验表明,PPM1D 特有的高度碱性环与底物特异性有关。我们提出了一种新的 PPM1D 催化位点模型和环状肽抑制模型,这将对随后设计 PPM1D 抑制剂和鉴定新的底物都非常有用。

相似文献

10
WIP1 phosphatase as a potential therapeutic target in neuroblastoma.WIP1磷酸酶作为神经母细胞瘤的潜在治疗靶点。
PLoS One. 2015 Feb 6;10(2):e0115635. doi: 10.1371/journal.pone.0115635. eCollection 2015.

引用本文的文献

5
The role of PPM1D in cancer and advances in studies of its inhibitors.PPM1D 在癌症中的作用及其抑制剂研究进展。
Biomed Pharmacother. 2020 May;125:109956. doi: 10.1016/j.biopha.2020.109956. Epub 2020 Jan 29.
8
WIP1 phosphatase as pharmacological target in cancer therapy.WIP1磷酸酶作为癌症治疗中的药理学靶点。
J Mol Med (Berl). 2017 Jun;95(6):589-599. doi: 10.1007/s00109-017-1536-2. Epub 2017 Apr 24.

本文引用的文献

4
Clinical developments in nanotechnology for cancer therapy.癌症治疗纳米技术的临床进展。
Pharm Res. 2011 Feb;28(2):187-99. doi: 10.1007/s11095-010-0178-7. Epub 2010 Jun 12.
5
Targeting of drugs and nanoparticles to tumors.药物和纳米颗粒对肿瘤的靶向作用。
J Cell Biol. 2010 Mar 22;188(6):759-68. doi: 10.1083/jcb.200910104. Epub 2010 Mar 15.
7
CHARMM: the biomolecular simulation program.CHARMM:生物分子模拟程序。
J Comput Chem. 2009 Jul 30;30(10):1545-614. doi: 10.1002/jcc.21287.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验